BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 23849964)

  • 1. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
    Sardella G; Lucisano L; Mancone M; Conti G; Calcagno S; Stio RE; Pennacchi M; Biondi-Zoccai G; Canali E; Fedele F
    Int J Cardiol; 2013 Oct; 168(4):3715-20. PubMed ID: 23849964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial.
    Sardella G; Conti G; Donahue M; Mancone M; Canali E; De Carlo C; Di Roma A; Calcagno S; Lucisano L; Fedele F
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E36-43. PubMed ID: 22517610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study.
    Zemánek D; Branny M; Martinkovičová L; Hájek P; Malý M; Tesař D; Tomašov P; Veselka J
    Int J Cardiol; 2013 Oct; 168(3):2494-7. PubMed ID: 23597577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
    Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
    J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study.
    Veselka J; Zemánek D; Hájek P; Malý M; Adlová R; Martinkovicová L; Tesar D
    Am J Cardiol; 2009 Sep; 104(5):630-3. PubMed ID: 19699335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.
    Briguori C; Visconti G; Focaccio A; Golia B; Chieffo A; Castelli A; Mussardo M; Montorfano M; Ricciardelli B; Colombo A
    J Am Coll Cardiol; 2009 Dec; 54(23):2157-63. PubMed ID: 19664895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in female patients with non-ST-segment elevation acute coronary syndrome.
    Gao Y; Jia ZM; Sun YJ; Zhang ZH; Ren LN; Qi GX
    Chin Med J (Engl); 2012 Jul; 125(13):2250-4. PubMed ID: 22882843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
    Yun KH; Jeong MH; Oh SK; Rhee SJ; Park EM; Lee EM; Yoo NJ; Kim NH; Ahn YK; Jeong JW
    Int J Cardiol; 2009 Nov; 137(3):246-51. PubMed ID: 18706705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 study).
    Veselka J; Hájek P; Tomašov P; Tesař D; Brůhová H; Matějovič M; Branny M; Studenčan M; Zemánek D
    Am J Cardiol; 2014 Feb; 113(3):446-51. PubMed ID: 24304551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.
    Di Sciascio G; Patti G; Pasceri V; Gaspardone A; Colonna G; Montinaro A
    J Am Coll Cardiol; 2009 Aug; 54(6):558-65. PubMed ID: 19643320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing nonemergency percutaneous coronary intervention.
    Gordin J; Haider A; Swaminathan RV; Kim LK; Minutello RM; Bergman G; Wong SC; Feldman DN
    Am J Cardiol; 2012 Nov; 110(10):1397-404. PubMed ID: 22858186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
    Patti G; Pasceri V; Colonna G; Miglionico M; Fischetti D; Sardella G; Montinaro A; Di Sciascio G
    J Am Coll Cardiol; 2007 Mar; 49(12):1272-8. PubMed ID: 17394957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can a high reloading dose of atorvastatin prior to percutaneous coronary intervention reduce periprocedural myocardial infarction?
    Nafasi L; Rahmani R; Shafiee A; Salari A; Abdollahi A; Meysamie A
    Curr Med Res Opin; 2014 Mar; 30(3):381-6. PubMed ID: 23952289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.
    Pasceri V; Patti G; Nusca A; Pristipino C; Richichi G; Di Sciascio G;
    Circulation; 2004 Aug; 110(6):674-8. PubMed ID: 15277322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative rosuvastatin protects patients with coronary artery disease undergoing noncardiac surgery.
    Xia J; Qu Y; Yin C; Xu D
    Cardiology; 2015; 131(1):30-7. PubMed ID: 25832289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
    Kim JS; Kim J; Choi D; Lee CJ; Lee SH; Ko YG; Hong MK; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Lee NH; Cho YH; Cho DK; Jang Y
    JACC Cardiovasc Interv; 2010 Mar; 3(3):332-9. PubMed ID: 20298994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.
    Nusca A; Melfi R; Patti G; Sciascio GD
    Future Cardiol; 2010 Sep; 6(5):579-89. PubMed ID: 20932108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
    Kaya A; Kurt M; Tanboğa IH; Işik T; Ekinci M; Aksakal E; Kaya Y; Topçu S; Sevimli S
    Acta Cardiol; 2013 Oct; 68(5):489-94. PubMed ID: 24283110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of two-day atorvastatin pretreatment on long-term outcome of patients with stable angina pectoris undergoing elective percutaneous coronary intervention.
    Veselka J; Zemánek D; Hájek P; Malý M; Adlová R; Martinkovičová L; Tomašov P; Tesař D
    Am J Cardiol; 2011 May; 107(9):1295-9. PubMed ID: 21349484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin.
    Cay S; Cagirci G; Sen N; Balbay Y; Durmaz T; Aydogdu S
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):41-7. PubMed ID: 20217203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.